This past Friday, the US Food and Drug Administration (FDA) approved 2 drugs that could help our patients: fentanyl nasal spray (Lazanda, Archimedes Pharma) and rivaroxaban (Xarelto, Janssen Pharmaceuticals).
Lazanda is the first fentanyl nasal spray approved in the United States for breakthrough cancer pain (BTCP) in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Xarelto is approved for prophylaxis of deep vein thrombosis (DVT), although currently approved for use following hip or knee surgery.
Read the press release from Archimedes Pharma:
Read the press release from the FDA:
from Janssen Pharmaceuticals: